Form 8-K - Current report:
SEC Accession No. 0001213900-26-070193
Filing Date
2026-06-18
Accepted
2026-06-18 17:00:24
Documents
11
Period of Report
2026-06-18
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0295259-8k_actinium.htm   iXBRL 8-K 21474
  Complete submission text file 0001213900-26-070193.txt   185726

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE atnm-20260618.xsd EX-101.SCH 3032
3 XBRL LABEL FILE atnm-20260618_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE atnm-20260618_pre.xml EX-101.PRE 22370
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0295259-8k_actinium_htm.xml XML 3218
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 261103835
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)